Rhumbline Advisers Sangamo Therapeutics, Inc Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 01, 2024	SELL	$0.36 - $0.65 $57,302 - $103,462	-159,173 Reduced 72.74%	59,653 $21,000
Q1 2024 May 09, 2024	BUY	$0.42 - $1.38 $1,519 - $4,994	3,619 Added 1.68%	218,826 $146,000
Q4 2023 Feb 08, 2024	SELL	$0.3 - $0.63 $27 - $56	-90 Reduced 0.04%	215,207 $116,000
Q3 2023 Nov 09, 2023	BUY	$0.58 - $1.47 $1,832 - $4,643	3,159 Added 1.49%	215,297 $129,000
Q2 2023 Aug 08, 2023	BUY	$1.11 - $1.74 $2,629 - $4,122	2,369 Added 1.13%	212,138 $275,000
Q1 2023 May 11, 2023	BUY	$1.66 - $3.67 $26,017 - $57,519	15,673 Added 8.07%	209,769 $369,000
Q4 2022 Feb 14, 2023	BUY	$2.77 - $5.07 $15,960 - $29,213	5,762 Added 3.06%	194,096 $609,000
Q3 2022 Nov 10, 2022	BUY	$4.27 - $6.39 $70,886 - $106,080	16,601 Added 9.67%	188,334 $923,000
Q2 2022 Aug 11, 2022	BUY	$3.28 - $6.21 $131,291 - $248,573	40,028 Added 30.39%	171,733 $711,000
Q1 2022 May 12, 2022	SELL	$5.23 - $7.82 $43,142 - $64,507	-8,249 Reduced 5.89%	131,705 $765,000
Q4 2021 Feb 10, 2022	SELL	$7.29 - $10.97 $15,644 - $23,541	-2,146 Reduced 1.51%	139,954 $1.05 Million
Q3 2021 Nov 12, 2021	BUY	$9.01 - $12.01 $38,607 - $51,462	4,285 Added 3.11%	142,100 $1.28 Million
Q2 2021 Aug 05, 2021	SELL	$10.17 - $12.64 $68,088 - $84,624	-6,695 Reduced 4.63%	137,815 $1.65 Million
Q1 2021 May 06, 2021	SELL	$10.88 - $17.05 $131,832 - $206,594	-12,117 Reduced 7.74%	144,510 $1.81 Million
Q4 2020 Feb 10, 2021	BUY	$9.23 - $18.18 $49,666 - $97,826	5,381 Added 3.56%	156,627 $2.44 Million
Q3 2020 Nov 12, 2020	SELL	$9.38 - $12.48 $398,687 - $530,449	-42,504 Reduced 21.94%	151,246 $1.43 Million
Q2 2020 Aug 13, 2020	BUY	$6.21 - $11.83 $150,195 - $286,120	24,186 Added 14.26%	193,750 $1.74 Million
Q1 2020 May 06, 2020	BUY	$5.05 - $8.85 $30,148 - $52,834	5,970 Added 3.65%	169,564 $1.08 Million
Q4 2019 Feb 05, 2020	BUY	$8.03 - $11.7 $57,607 - $83,935	7,174 Added 4.59%	163,594 $1.37 Million
Q3 2019 Oct 23, 2019	BUY	$9.05 - $12.22 $51,431 - $69,446	5,683 Added 3.77%	156,420 $1.42 Million
Q2 2019 Aug 14, 2019	BUY	$8.75 - $13.03 $158,707 - $236,338	18,138 Added 13.68%	150,737 $1.62 Million
Q1 2019 May 01, 2019	SELL	$7.72 - $12.81 $15,625 - $25,927	-2,024 Reduced 1.5%	132,599 $1.27 Million
Q4 2018 Jan 31, 2019	BUY	$9.51 - $16.6 $412,905 - $720,738	43,418 Added 47.6%	134,623 $1.55 Million
Q3 2018 Nov 07, 2018	SELL	$13.05 - $19.05 $85,542 - $124,872	-6,555 Reduced 6.71%	91,205 $1.55 Million
Q2 2018 Aug 06, 2018	BUY	$13.9 - $19.8 $261,528 - $372,537	18,815 Added 23.83%	97,760 $1.39 Million
Q1 2018 May 02, 2018	SELL	$16.7 - $26.35 $1,452 - $2,292	-87 Reduced 0.11%	78,945 $1.5 Million
Q4 2017 Feb 09, 2018	SELL	$11.6 - $17.35 $113,494 - $169,752	-9,784 Reduced 11.02%	79,032 $1.3 Million
Q3 2017 Nov 06, 2017	BUY	$8.4 - $15.0 $746,054 - $1.33 Million	88,816	88,816 $1.33 Million

Others Institutions Holding SGMO

# of Institutions

118

Shares Held

43.8M

Call Options Held

576K

Put Options Held

1.17M

Vanguard Group Inc Valley Forge, PA

9.37M
Shares

$11 Million
0.0% of portfolio
Wasatch Advisors Inc Salt Lake City, UT

9.23M
Shares

$10.8 Million
0.05% of portfolio
State Street Corp Boston, MA

5.02M
Shares

$5.87 Million
0.0% of portfolio
Black Rock Inc. New York, NY

4.7M
Shares

$5.5 Million
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

3.08M
Shares

$3.61 Million
0.0% of portfolio

View Full List

About SANGAMO THERAPEUTICS, INC

Ticker SGMO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 156,552,992
Market Cap $183M
Description
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucle...

More about SGMO

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account